COMMUNIQUÉS West-GlobeNewswire

SmallCap Sentinel: A Hundred Times Better

27/09/2019 - 13:00

ORLANDO, Fla., Sept. 27, 2019 (GLOBE NEWSWIRE) -- The legal cannabis industry- both in the United States and Canada- is evolving. Opportunities abound in this green revolution but the path to market is far from [...]

Trevena to Present at the 2019 Cantor Global Healthcare Conference

27/09/2019 - 13:00

CHESTERBROOK, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous [...]

EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting

27/09/2019 - 13:00

WATERTOWN, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today [...]

Osmotica Pharmaceuticals plc Appoints Industry Executive Michael J. DeBiasi to Board of Directors

27/09/2019 - 12:50

BRIDGEWATER, N.J., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced the appointment of Michael J [...]

Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder

27/09/2019 - 12:35

GAITHERSBURG, Md., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National [...]

AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference

27/09/2019 - 12:30

SAN DIEGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation [...]

Press news Biocartis Group: Results of the Special Shareholders’ Meeting held on 27 September 2019

27/09/2019 - 11:00

PRESS RELEASE : REGULATED INFORMATION 27 September 2019, 11:00 CEST Results of the Special Shareholders’ Meeting held on 27 September 2019 Mechelen, Belgium, 27 September 2019 – Biocartis Group NV (the ‘Company’ or ‘ [...]

BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development

27/09/2019 - 10:00

BrainStorm Holds a Roundtable Discussion with ALS Advocacy Group Leaders NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative [...]

Philips showcases commitment to improving respiratory care at ERS 2019

27/09/2019 - 10:00

September 27, 2019 Broad portfolio of integrated sleep and respiratory solutions connect data, technology and people across the care continuum Amsterdam, the Netherlands and Madrid, Spain – Royal Philips (NYSE: PHG, AEX [...]

AgraFlora Organics Bolsters European Supply Agreement; Receives C$2,000,000 Cash Infusion

27/09/2019 - 09:05

VANCOUVER, British Columbia, Sept. 27, 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“ AgraFlora ” or the “ Company ”) ( CSE: AGRA) (Frankfurt: PU31) (OTCPK: PUFXF ), a growth oriented and diversified [...]

Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study

27/09/2019 - 09:00

NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]

Nexstim New System Sales Update

27/09/2019 - 08:30

Press Release, Helsinki, 27 September 2019 at 9.30 am (EET) Nexstim New System Sales Update Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company")—the company developing and marketing a unique brain stimulation [...]

Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting

27/09/2019 - 08:00

Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting KY1044 increases the ratio of intratumoral cytotoxic-to-regulatory T cells and induces tumor regression Expanding [...]

Nicox Completes Enrolment of NCX 4251 Phase 2 Trial with Top-Line Results on Track for Q4 2019

27/09/2019 - 07:30

Press Release Nicox Completes Enrolment of NCX 4251 Phase 2 Trial with Top-Line Results on Track for Q4 2019 September 27, 2019 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, [...]

Nicox : Recrutement terminé dans l’étude clinique de phase 2 pour le NCX 4251 – Premiers résultats attendus au quatrième trimestre 2019

27/09/2019 - 07:30

Communiqué de presse Nicox : Recrutement terminé dans l’étude clinique de phase 2 pour le NCX 4251 – Premiers résultats attendus au quatrième trimestre 2019 27 septembre 2019 – diffusion à 7h30 Sophia Antipolis, France [...]

ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019

27/09/2019 - 07:00

Geneva, Switzerland and Boston, MA – September 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for [...]

Bone Therapeutics to present data from its Phase II/III trial with JTA-004 at the 2nd World Congress on Rheumatology & Orthopedics

27/09/2019 - 07:00

Press release Gosselies, Belgium, 27 September 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies [...]

Bone Therapeutics présentera les données cliniques de la phase II/III de l’essai évaluant JTA-004 à l’occasion du 2ème Congrès Mondial de Rhumatologie et d’Orthopédie (WCRO)

27/09/2019 - 07:00

Communiqué de presse Gosselies, Belgique, le 27 septembre 2019, 07h00 CEST – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE, éligible PEA-PME), société de biotechnologie spécialisée dans le développement de [...]

MDxHealth Successfully Completes a EUR 9.0 Million (USD 9.8 Million)(1) Capital Increase

27/09/2019 - 06:00

Press release Regulated information – Inside information 27 September 2019, 6:00 a.m. CEST IRVINE, CA, and HERSTAL, BELGIUM – 27 September 2019 – MDxHealth SA (Euronext Brussels: MDXH) (the " Company " or " MDxHealth [...]